aDepartment of Infectious Diseases, Pediatric’s Center of Excellence, Children’s Medical Center, Tehran University of Medical Sciences, Tehran, Iran
bNon-Communicable Pediatric Diseases Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran
cDepartment of Pathology, Shafa Hospital, Qazvin University of Medical Sciences, Qazvin, Iran
dDepartment of Microbiology and Virology, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
eDepartment of Microbiology, Faculty of Medicine, Guilan University of Medical Sciences, Rasht, Iran
fDepartment of Microbiology, Faculty of Medicine, Babol University of Medical Sciences, Babol, Iran
gStudent Research Committee, Babol University of Medical Sciences, Babol, Iran
hInfectious Diseases and Tropical Medicine Research Center, Babol University of Medical Sciences, Babol, Iran
Copyright ©2019, Korea Centers for Disease Control and Prevention
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Conflicts of Interest
The authors declare that they have no conflicts of interest.
Reactions | Target genes | Primer sequence (5′ → 3′) | Amplicon size (bp) | References |
---|---|---|---|---|
S1 | mecA |
F 5′-TCCAGATTACAACTTCACCAGG-3′ R 5′-CCACTTCATATCTTGTAACG-3′ |
310 | [12] |
ermA |
F 5′-TATCTTATCGTTGAGAAGGGATT-3′ R 5′-CTACACTTGGCTTAGGATGAAA-3′ |
139 | [13] | |
ereB |
F 5′-AGAAATGGAGGTTCATACTTACCA-3′ R 5′-CATATAATCATCACCAATGGCA-3′ |
546 | ||
|
||||
S2 | ermB |
F 5′-CCGTTTACGAAATTGGAACAGGTAAAGGGC-3′ R 5′-GAATCGAGACTTGAGTGTGC-3′ |
359 | |
ermC |
F 5′- ATCTTTGAAATCGGCTCAGG -3′ R 5′- CAAACCCGTATTCCACGATT -3′ |
295 | ||
msrA |
F 5′-TCCAATCATTGCACAAAATC-3′ R 5′- AATTCCCTCTATTTGGTGGT-3′ |
163 | [14] | |
msrB |
F 5′-TATGATATCCATAATAATTATCCAATC-3′ R 5′-AAGTTATATCATGAATAGATTGTCCTGTT-3′ |
595 | [15] | |
ereA |
F 5′- AACACCCTGAACCCAAGGGACG-3′ R 5- 5′-CTTCACATCCGGATTCGCTCGA-3′ |
420 | [16] |
Reactions | Target genes | Primer sequence (5′ → 3′) | Amplicon size (bp) | References |
---|---|---|---|---|
S1 | mecA | F 5′-TCCAGATTACAACTTCACCAGG-3′ R 5′-CCACTTCATATCTTGTAACG-3′ |
310 | [ |
ermA | F 5′-TATCTTATCGTTGAGAAGGGATT-3′ R 5′-CTACACTTGGCTTAGGATGAAA-3′ |
139 | [ | |
ereB | F 5′-AGAAATGGAGGTTCATACTTACCA-3′ R 5′-CATATAATCATCACCAATGGCA-3′ |
546 | ||
| ||||
S2 | ermB | F 5′-CCGTTTACGAAATTGGAACAGGTAAAGGGC-3′ R 5′-GAATCGAGACTTGAGTGTGC-3′ |
359 | |
ermC | F 5′- ATCTTTGAAATCGGCTCAGG -3′ R 5′- CAAACCCGTATTCCACGATT -3′ |
295 | ||
msrA | F 5′-TCCAATCATTGCACAAAATC-3′ R 5′- AATTCCCTCTATTTGGTGGT-3′ |
163 | [ | |
msrB | F 5′-TATGATATCCATAATAATTATCCAATC-3′ R 5′-AAGTTATATCATGAATAGATTGTCCTGTT-3′ |
595 | [ | |
ereA | F 5′- AACACCCTGAACCCAAGGGACG-3′ R 5- 5′-CTTCACATCCGGATTCGCTCGA-3′ |
420 | [ |
No. of antimicrobial resistance | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
GM | ERY | AM | CC | CP | FOX | TE | MUP | SXT | RA | LNZ | |
S | 5 (4.7) | 9 (8.5) | 11 (10.3) | 25 (23.5) | 16 (15.1) | 0 (0.0) | 18 (16.9) | 92 (86.7) | 32 (30.2) | 94 (88.6) | 106 (100) |
| |||||||||||
I | 5 (4.7) | 12 (11.3) | 2 (1.8) | 8 (7.5) | 6 (5.6) | 0 (0.0) | 4 (3.7) | 0 (0.0) | 3 (2.8) | 0 (0.0) | 0 (0.0) |
| |||||||||||
R | 96 (90.6) | 85 (80.2) | 93 (87.7) | 73 (68.8) | 84 (79.2) | 106 (100) | 84 (79.2) | 14 (13.2) | 71 (66.9) | 12 (11.3) | 0 (0.0) |
Genes | Types of resistant phenotypes | Total (N = 46) | |||
---|---|---|---|---|---|
| |||||
cMLSB (n = 27) | iMLSB (n = 11) | MS (n = 8) | |||
erm type genes | ermA | 7 (25.9) | 6 (54.5) | 1 (12.5) | 14 (30.4) |
ermB | 5 (18.5) | 7 (63.6) | 0 (0.0) | 12 (26.1) | |
ermC | 12 (44.4) | 9 (81.8) | 3 (37.5) | 24 (52.2) | |
| |||||
ere type genes | ereA | 3 (11.1) | 2 (18.2) | 0 (0.0) | 5 (10.8) |
ereB | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
| |||||
Combination of erm genes | ermA+ ermB | 1(3.7) | 0 (0.0) | 0 (0.0) | 1 (2.2) |
ermA+ermC | 6 (22.2) | 0 (0.0) | 0 (0.0) | 6 (13.1) | |
ermC+ermB | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
ermA+ermB+ermC | 4 (14.8) | 4 (36.4) | 0 (0.0) | 8 (17.4) | |
| |||||
Combination of erm/ere genes | ermC+ereA | 1 (3.7) | 0 (0.0) | 0 (0.0) | 1 (2.2) |
ermA/B/C +ereA | 0 (0.0) | 1 (9.1) | 0 (0.0) | 1 (2.2) | |
| |||||
PCR negative | 13 (48.1%) | 2 (18.2) | 4 (50) | 15 (24.6) |
Data are presented as AM = ampicillin; CC = clindamycin; CP = ciprofloxacin; ERY = erythromycin; FOX = cefoxitin; GM = gentamicin; I = intermediate; LNZ = linezolid; MUP = mupirocin; R = resistant; RA = rifampin; S = susceptible; SXT = trimethoprim-sulfamethoxazole; TE = tetracycline.
Data are presented as cMLSB = constitutive resistance macrolide, lincosamide, and streptogramin B; iMLSB = inducible resistance macrolide, lincosamide, and streptogramin B; MS = resistant to erythromycin and sensitive to clindamycin.